Angina Pectoris Drugs

Angina Pectoris Drugs Market by Type (Prinzmetal Angina, Stable Angina, Unstable Angina), Drugs (Anti-Ischemic Agents, Antihypertensive Agents, Antiplatelet Agents), Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the angina pectoris drugs market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[199 Pages Report] The Angina Pectoris Drugs Market size was estimated at USD 1.14 billion in 2023 and expected to reach USD 1.20 billion in 2024, at a CAGR 5.39% to reach USD 1.65 billion by 2030.

Angina Pectoris Drugs Market
To learn more about this report, request a free PDF copy
Angina pectoris drugs are pharmaceuticals designed to relieve or manage the symptoms of angina pectoris, a condition characterized by chest pain owing to reduced blood flow to the heart muscle. These medications aim to decrease the heart's need for oxygen and increase its supply, thereby mitigating the risk of a heart attack. Common classes of drugs for managing angina include nitrates, beta-blockers, calcium channel blockers, and antiplatelet drugs. The primary drivers include the prevalence of cardiovascular diseases globally, an aging population more susceptible to chronic diseases, and ongoing research and development activities leading to the introduction of innovative therapeutic options. Additionally, rising awareness among patients regarding the early diagnosis and management of angina pectoris fuels its adoption. Key restraints include the potential side effects and risks associated with angina pectoris drugs and the growing preference for non-pharmacological treatments such as angioplasty and coronary artery bypass grafting (CABG). Moreover, patent expirations of drugs and the subsequent emergence of generic drugs pose challenges. The challenges include stringent regulatory requirements for drug approval, high costs involved in developing new drugs, and the need for drugs that effectively manage angina without causing adverse side effects. Opportunities include the potential development of novel therapeutic agents with efficacy and lower side effects, expansion in emerging markets, and advancements in drug delivery technologies. Collaboration between pharmaceutical companies and research institutions for drug development also presents significant opportunities.
Market Dynamics

The market dynamics represent an ever-changing landscape of the Angina Pectoris Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Increasing burden of lifestyle diseases couple with rise in cases of heart related disorders
    • Augmentation of novel drug delivery systems
    • Government suppport in strengthening the prevention and control of cardiovascular disease
  • Market Restraints
    • Concerns regarding side effects associated with certain drug classes
  • Market Opportunities
    • Technological advancements towards personalized cardiovascular medicine
    • Proliferation in the number of drug approvals and clinical research
  • Market Challenges
    • Dearth of skilled and experienced professionals
Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Angina Pectoris Drugs Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Angina Pectoris Drugs Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Angina Pectoris Drugs Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Angina Pectoris Drugs Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Angina Pectoris Drugs Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Angina Pectoris Drugs Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Angina Pectoris Drugs Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Angina Pectoris Drugs Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Angina Pectoris Drugs Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Angina Pectoris Drugs Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Angina Pectoris Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Angina Pectoris Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Angina Pectoris Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Angina Pectoris Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Centurion Remedies Private Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Mankind Pharma, Merck & Co. Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sumitomo Corporation, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Angina Pectoris Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Angina Pectoris Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Prinzmetal Angina
    • Stable Angina
    • Unstable Angina
  • Drugs
    • Anti-Ischemic Agents
    • Antihypertensive Agents
    • Antiplatelet Agents
    • Beta-Adrenergic Blocking Agents
    • Calcium Channel Blockers
    • Nitrates
    • Statins
  • Route of Administration
    • Oral
    • Parenteral
    • Transdermal
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End-Users
    • Homecare
    • Hospitals
    • Specialty Clinics

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Angina Pectoris Drugs Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Angina Pectoris Drugs Market, by Type
  7. Angina Pectoris Drugs Market, by Drugs
  8. Angina Pectoris Drugs Market, by Route of Administration
  9. Angina Pectoris Drugs Market, by Distribution Channel
  10. Angina Pectoris Drugs Market, by End-Users
  11. Americas Angina Pectoris Drugs Market
  12. Asia-Pacific Angina Pectoris Drugs Market
  13. Europe, Middle East & Africa Angina Pectoris Drugs Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 474]
  18. List of Companies Mentioned [Total: 25]
Understanding Angina Pectoris Drugs – A Comprehensive Guide
January 24, 2024
Understanding Angina Pectoris Drugs – A Comprehensive Guide
With our fast-paced lives and increasingly sedentary lifestyles, we are more prone to health risks than ever before. One such risk is the onset of heart-related disorders, such as Angina Pectoris. Angina is a type of chest discomfort arising from a lack of oxygen in the heart muscles. If left untreated, Angina can lead to more severe conditions like heart attacks and strokes. Therefore, getting the right treatment is essential. The good news is that specific medications are available to manage Angina Pectoris.


Nitrates are widely used as Angina Pectoris drugs. These drugs cause vasodilation (the widening of blood vessels), thereby increasing the blood flow to the heart, reducing the workload on the organ, and relieving chest pain. Examples of Nitrates include Nitroglycerin and Isosorbide.


Beta-blockers are drugs that inhibit the action of adrenaline and other stress hormones, which can otherwise elevate the heart rate and increase the workload on the organ. Beta-blockers also reduce blood pressure, thereby easing the workload on the heart.

Calcium-channel blockers:

These are Angina Pectoris drugs that prevent calcium influx into the heart cells, causing them to relax. This, in turn, dilates the blood vessels, increases the blood flow to the heart, and relieves chest pain. Examples of Calcium-channel blockers include Nifedipine, Amlodipine, and Diltiazem.


Aspirin is a blood thinner drug that reduces the likelihood of blood clots in the arteries that supply the heart with blood, reducing the risk of heart attacks and further complications. Aspirin is often used in conjunction with other Angina Pectoris drugs.


Ranolazine is a relatively new drug that helps regulate the heart's calcium channels and metabolic pathways, improving the heart's function, reducing the organ's workload, and relieving chest pain.

Angina Pectoris, if not treated on time, can lead to fatal consequences. Therefore, getting the right medication is crucial to managing the condition. From Nitrates to Beta-blockers, Calcium-channel blockers, and Aspirin, various options can help eliminate chest pain and improve heart function. It is always advisable to consult your doctor for the right medication and dosage, as self-medicating can have severe consequences.

Frequently Asked Questions
  1. How big is the Angina Pectoris Drugs Market?
    Ans. The Global Angina Pectoris Drugs Market size was estimated at USD 1.14 billion in 2023 and expected to reach USD 1.20 billion in 2024.
  2. What is the Angina Pectoris Drugs Market growth?
    Ans. The Global Angina Pectoris Drugs Market to grow USD 1.65 billion by 2030, at a CAGR of 5.39%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.